drugset / Trial / NCT07381829

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

NCT07381829

Phase 1 Recruiting 328 enrolled HC Biopharma Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced lung cancer and determine the recommended dose for subsequent studies.

Timeline

Start
2025-10-27
Primary completion
2026-12-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HC010 Unknown Intravenous
Background Carboplatin Small molecule
Background Cisplatin Other / unclassified
Background Docetaxel Small molecule
Background Etoposide Small molecule
Background Paclitaxel Small molecule
Background Pemetrexed Small molecule

Indications

No indication recorded.